In vitro development of rifampin resistance in clinical isolates of Haemophilus influenzae type b

R. Yogev, C. Melick, W. Glogowski

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Although all of 14 clinical isolates of Haemophilus influenzae type b strains demonstrated rifampin susceptibility in vitro (minimal inhibitory concentration ≤0.4 μg/ml) when an inoculum of 104 colony-forming units (CFU) was used, 10 of the 14 strains manifested resistance to this agent when an inoculum of 108 CFU was tested. The mutation rate for rifampin resistance ranged from 1 resistant colony per 3.5 x 106 CFU to 1 per 4 x 107 CFU. The emergence of rifampin-resistant mutants was prevented when trimethoprim was combined with rifampin. This finding suggests that when used alone for prophylaxis of H. influenzae type b nasopharyngeal carriers, rifampin is likely to lead to the emergence of resistant strains.

Original languageEnglish (US)
Pages (from-to)387-389
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume21
Issue number3
DOIs
StatePublished - 1982

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'In vitro development of rifampin resistance in clinical isolates of Haemophilus influenzae type b'. Together they form a unique fingerprint.

Cite this